US patent protects various aspects of the cell-based product including rhodamine derivative’s composition of matter, vital steps involved in ATIR manufacturing process and therapeutic use of ATIR in preventing graft-versus-host disease connected with allogeneic stem cell transplantations.
Kiadis Pharma chief executive officer Manfred Ruediger said, "We are delighted about the broad patent protection for ATIR in the world’s largest pharmaceutical market. This broad patent protection provides a strong basis for future commercialization of ATIR to the benefit of patients."
The cell-based product facilitates stem cell transplantations from incompatible family donors to patients suffering from blood cancer.
ATIR previously obtained orphan drug designation in EU and the US.